Nanomedicine against biofilm infections: A roadmap of challenges and limitations
- PMID: 38403876
- DOI: 10.1002/wnan.1944
Nanomedicine against biofilm infections: A roadmap of challenges and limitations
Abstract
Microbial biofilms are complex three-dimensional structures where sessile microbes are embedded in a polymeric extracellular matrix. Their resistance toward the host immune system as well as to a diverse range of antimicrobial treatments poses a serious health and development threat, being in the top 10 global public health threats declared by the World Health Organization. In an effort to combat biofilm-related microbial infections, several strategies have been developed to independently eliminate biofilms or to complement conventional antibiotic therapies. However, their limitations leave room for other treatment alternatives, where the application of nanotechnology to biofilm eradication has gained significant relevance in recent years. Their small size, penetration efficiency, and the design flexibility that they present makes them a promising alternative for biofilm infection treatment, although they also present set-backs. This review aims to describe the main possibilities and limitations of nanomedicine against biofilms, while covering the main aspects of biofilm formation and study, and the current therapies for biofilm treatment. This article is categorized under: Therapeutic Approaches and Drug Discovery > Nanomedicine for Infectious Disease Toxicology and Regulatory Issues in Nanomedicine > Toxicology of Nanomaterials Toxicology and Regulatory Issues in Nanomedicine > Regulatory and Policy Issues in Nanomedicine.
Keywords: antimicrobials; bacteria; biofilm; infectious diseases; microorganisms.
© 2024 The Authors. WIREs Nanomedicine and Nanobiotechnology published by Wiley Periodicals LLC.
References
REFERENCES
-
- Aflakian, F., Mirzavi, F., Aiyelabegan, H. T., Soleimani, A., Gholizadeh Navashenaq, J., Karimi-Sani, I., Rafati Zomorodi, A., & Vakili-Ghartavol, R. (2023). Nanoparticles-based therapeutics for the management of bacterial infections: A special emphasis on FDA approved products and clinical trials. European Journal of Pharmaceutical Sciences, 188, 106515. https://doi.org/10.1016/j.ejps.2023.106515
-
- Alcàcer-Almansa, J., Arévalo-Jaimes, B. V., Blanco-Cabra, N., & Torrents, E. (2023). Chapter 7-Methods for studying biofilms: Microfluidics and translation in the clinical context. In V. Gurtler & M. Patrauchan (Eds.), Methods in microbiology (Vol. 53, pp. 195-233). Academic Press. https://doi.org/10.1016/bs.mim.2023.04.002
-
- Alumutairi, L., Yu, B., Filka, M., Nayfach, J., & Kim, M.-H. (2020). Mild magnetic nanoparticle hyperthermia enhances the susceptibility of Staphylococcus aureus biofilm to antibiotics. International Journal of Hyperthermia, 37(1), 66-75. https://doi.org/10.1080/02656736.2019.1707886
-
- Al-Wrafy, F. A., Al-Gheethi, A. A., Ponnusamy, S. K., Noman, E. A., & Fattah, S. A. (2022). Nanoparticles approach to eradicate bacterial biofilm-related infections: A critical review. Chemosphere, 288, 132603. https://doi.org/10.1016/j.chemosphere.2021.132603
-
- Anju, V. T., Busi, S., Imchen, M., Kumavath, R., Mohan, M. S., Salim, S. A., Subhaswaraj, P., & Dyavaiah, M. (2022). Polymicrobial infections and biofilms: Clinical significance and eradication strategies. Antibiotics (Basel), 11(12), 1731. https://doi.org/10.3390/antibiotics11121731
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources

